MAP Pharmaceuticals, Inc.

140 articles about MAP Pharmaceuticals, Inc.

• Allergan Inc. Announces Expiration of Tender Offer for All Outstanding Shares of MAP Pharmaceuticals, Inc. and Intent to Exercise Top-Up Option to Effect a Short-Form Merger

  3/1/2013

• Allergan Inc. and MAP Pharmaceuticals, Inc. Announce the Federal Trade Commission Has Granted Early Termination of Waiting Period Under Hart-Scott-Rodino Act

  2/7/2013

• Allergan Inc. Commences Cash Tender Offer for All Outstanding Shares of MAP Pharmaceuticals, Inc.

  1/31/2013

• Allergan Inc. to Buy MAP Pharmaceuticals, Inc. for $958 Million

  1/23/2013

• MAP Pharmaceuticals, Inc. to Present at the 31st Annual J.P. Morgan Healthcare Conference

  1/3/2013

• MAP Pharmaceuticals, Inc. Announces FDA Acceptance for Filing of NDA Resubmission for LEVADEX&#0174

  11/26/2012

• MAP Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

  11/9/2012

• MAP Pharmaceuticals, Inc. Reports Third Quarter of 2012 Financial Results

  11/2/2012

• MAP Pharmaceuticals, Inc. Resubmits New Drug Application to FDA for LEVADEX&#0174 Orally Inhaled Migraine Drug

  10/16/2012

• MAP Pharmaceuticals, Inc. Announces Full Exercise of Underwriter's Option to Purchase Additional Shares of Common Stock

  8/30/2012

• MAP Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

  8/9/2012

• MAP Pharmaceuticals, Inc. Prices Public Offering of Common Stock

  8/1/2012

• MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

  8/1/2012

• MAP Pharmaceuticals, Inc. Reports Second Quarter of 2012 Financial Results

  7/24/2012

• MAP Pharmaceuticals, Inc. to Resubmit Application for Migraine Treatment This Year

  6/26/2012

• MAP Pharmaceuticals, Inc. to Present Data on LEVADEX&#0174 at the 54th Annual Scientific Meeting of the American Headache Society

  6/25/2012

• MAP Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

  5/1/2012

• MAP Pharmaceuticals, Inc. to Meet FDA to Discuss Manufacturing Issues; Provides Update on LEVADEX

  4/16/2012

• MAP Pharmaceuticals, Inc. Reports 2011 Fourth Quarter and Year End Financial Results

  3/29/2012

• MAP Pharmaceuticals, Inc. Shares Dive After FDA Rejects Migraine Drug; Stock Down -0.82(4.78%) @ 12:53PM EDT

  3/27/2012